EMA Authorised: Rixubis (nonacog gamma) — Baxalta Innovations GmbH

View source ↗

Summary

The European Medicines Agency authorised Rixubis (nonacog gamma) by Baxalta Innovations GmbH for the treatment of Hemophilia B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• RIXUBIS (recombinant coagulation factor IX)

Snippet

Status: Authorised. Therapeutic area: Hemophilia B. MAH: Baxalta Innovations GmbH. Decision date: 22/09/2022